Presle N, Lapicque F, Fournel-Gigleux S, Magdalou J, Netter P
Laboratoire de Pharmacologie, URA CNRS 1288, Faculté de Médecine, Vandoeuvre les Nancy, France.
Drug Metab Dispos. 1996 Oct;24(10):1050-7.
We have previously shown that the acyl glucuronide of racemic ketoprofen can irreversibly bind in vitro to plasma proteins (Dubois, N., et ai., Drug Metab. Dispos. 21, 617-623, 1993), but the mechanism of the reaction has not been characterized. In the present study, the reactivity toward albumin of the glucuronide of both ketoprofen enantiomers was investigated. The extent of binding increased with the concentration of both protein and glucuronide. However, the two diastereoisomers showed different reactivities toward human serum albumin (HSA): the maximum yield of adducts with the glucuronide of the S-enantiomer was twice that obtained with the glucuronide of its antipode. The maximum extent of irreversible binding was at 4 hr for the R-ketoprofen conjugate, but was later for the S-form. Chemical modifications of albumin indicated that the glucuronide of the S-isomer reacted only with lysine residues, whereas the R-form linked covalently mainly with tyrosine residues and secondarily with lysine residues. A competition study using specific binding probes and fatty acids showed that the conjugates of S- and R-ketoprofen reacted with amino acids located in sites I and II of HSA, respectively. Taken together, these findings suggest that the irreversible binding of ketoprofen to albumin depends on the stereochemistry of the aglycon: the R-enantiomer binds to site II of the protein probably by a nucleophilic attack by tyrosine and/or lysine residues, whereas adduct formation via the conjugate of the S-enantiomer could occur at site I of HSA by the Schiff base mechanism. This irreversible binding at sites I and II may affect the major function of albumin (i.e. the transport of drugs and endogenous compounds).
我们之前已经表明,消旋酮洛芬的酰基葡糖醛酸在体外可与血浆蛋白不可逆结合(Dubois, N.等人,《药物代谢与处置》21, 617 - 623, 1993),但该反应机制尚未明确。在本研究中,对酮洛芬两种对映体的葡糖醛酸与白蛋白的反应活性进行了研究。结合程度随蛋白质和葡糖醛酸浓度的增加而升高。然而,两种非对映异构体对人血清白蛋白(HSA)表现出不同的反应活性:S - 对映体的葡糖醛酸形成加合物的最大产率是其对映体葡糖醛酸的两倍。R - 酮洛芬缀合物的不可逆结合最大程度在4小时时出现,而S - 型则较晚。白蛋白的化学修饰表明,S - 异构体的葡糖醛酸仅与赖氨酸残基反应,而R - 型主要与酪氨酸残基共价连接,其次与赖氨酸残基连接。使用特异性结合探针和脂肪酸的竞争研究表明,S - 和R - 酮洛芬的缀合物分别与位于HSA位点I和II的氨基酸反应。综上所述,这些发现表明酮洛芬与白蛋白的不可逆结合取决于苷元的立体化学:R - 对映体可能通过酪氨酸和/或赖氨酸残基的亲核攻击与蛋白质的位点II结合,而通过S - 对映体的缀合物形成加合物可能通过席夫碱机制在HSA的位点I发生。在位点I和II的这种不可逆结合可能会影响白蛋白的主要功能(即药物和内源性化合物的转运)。